CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I
The treatment choice of differentiated thyroid cancer resistant to therapy 131I to be restricted just to systemic methods. Traditional chemotherapy demonstrated no clinically relevant effectiveness but high toxicity. With the introduction into clinical practice of multi-kinase inhibitor was able to...
Saved in:
| Main Authors: | P. A. Isaev, P. O. Rumyantsev, V. V. Polkin, A. A. Ilyin, D. Yu. Syomin, T. A. Agababyan, S. V. Vasilkov, V. S. Medvedev |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2015-04-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/52 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Neoadjuvant target therapy of differentiated thyroid cancer (clinical observation)
by: P. A. Isaev, et al.
Published: (2017-04-01) -
THE USE OF SORAFENIB (NEXAVAR) IN TREATMENT OF PATIENT WITH DISSEMINATED PARATHYROID CANCER: A CASE REPORT
by: V. A. Gorbunova, et al.
Published: (2017-04-01) -
Approaches to conducting a physiologically relevant test (PRT) in the study of medicines containing substance IIc of the BCS subclass using sorafenib as an example
by: A. V. Suvorova, et al.
Published: (2024-09-01) -
Targeting AMP‐activated kinase impacts hepatocellular cancer stem cells induced by long‐term treatment with sorafenib
by: Alicia Bort, et al.
Published: (2019-05-01) -
Side skin reactions of multikinase inhibitors in treatment of thyroid cancer
by: F. S. Sevryukov, et al.
Published: (2021-01-01)